How GLP-1 Medications Actually Work in Your Body

GLP-1, short for glucagon-like peptide-1, is one of two main 'incretin' hormones released by L cells in your small intestine after you eat. Within minutes of a meal, GLP-1 levels rise and tell the pancreas to release insulin in proportion to the carbohydrate load, while suppressing glucagon (which raises blood sugar). GLP-1 also slows the rate at which the stomach empties into the small intestine, which spreads carbohydrate absorption out and reduces post-meal blood sugar peaks. In the brain, GLP-1 receptors in the hypothalamus and brainstem help generate the feeling of fullness. People with type 2 diabetes and obesity often have a blunted GLP-1 response after meals, which contributes to high blood sugar and a weaker satiety signal.

Natural GLP-1 only lasts a few minutes in the bloodstream because an enzyme called DPP-4 breaks it down quickly. Medications like semaglutide, liraglutide, and tirzepatide are engineered analogues: their amino acid sequences are tweaked and they are bound to a fatty acid that lets them stick to albumin in the blood. This combination shields them from DPP-4 and lets them circulate for days. Once-weekly formulations like Ozempic, Wegovy, Mounjaro, and Zepbound have half-lives near a week, which is why a single injection produces steady appetite suppression for seven days.

Three mechanisms work together. First, slower gastric emptying means food stays in the stomach longer, so people feel full faster and stay full longer. Second, central appetite suppression in the hypothalamus and brainstem reduces hunger signals and shrinks meal size. Third, reduced food reward in the dopaminergic brain circuits quiets the constant pull toward palatable foods, the experience patients describe as 'food noise.' The combination typically reduces daily calorie intake by 20% to 40% without conscious dieting. The STEP and SURMOUNT trials showed average weight losses of 15% to 22.5% over 68 to 72 weeks.

GIP, or glucose-dependent insulinotropic polypeptide, is the other main incretin hormone. It also boosts insulin release after meals and has direct effects on fat tissue and energy expenditure. Researchers debated for years whether activating GIP receptors helped or hurt obesity outcomes, since older work suggested GIP might promote fat storage. The SURMOUNT-1 and SURMOUNT-5 trials showed that combining GLP-1 and GIP activity in tirzepatide produced more weight loss than GLP-1 activity alone. The leading hypothesis is that GIP improves fat tissue function and may reduce nausea, allowing patients to tolerate higher effective GLP-1 activity.

Unlike older diabetes drugs such as sulfonylureas, GLP-1 receptor agonists trigger insulin release only when blood sugar is high. As glucose drops to normal, insulin secretion shuts off. This glucose-dependent action is why GLP-1 medications carry a much lower risk of low blood sugar (hypoglycemia) when used alone. Risk does rise if you also take insulin or sulfonylureas, which is why prescribers typically reduce those doses when starting a GLP-1. The FLOW trial in chronic kidney disease and the SELECT trial in cardiovascular disease showed additional benefits beyond glucose control, including reduced kidney decline and a 20% reduction in major cardiovascular events.

The same slowing of stomach emptying that produces fullness also explains most side effects. When food sits in the stomach longer, some people experience nausea, bloating, reflux, or sulfur burps. As the body adapts to the new pace of digestion, these symptoms usually fade over a few weeks. Slower titration, smaller meals, lower-fat foods, adequate hydration, and avoiding alcohol on injection day all reduce GI side effects. About 5% to 10% of patients in trials discontinued GLP-1s due to side effects, often during the first dose escalation.

The medication clears from your system over five to six weeks, and the GLP-1 receptors return to their baseline state. Appetite, food noise, and gastric emptying speed all revert. The STEP 1 extension trial found that participants who stopped semaglutide regained about two-thirds of their lost weight within a year. This is consistent with how chronic conditions are typically managed: stopping the medication ends the treatment effect. Newer research, including SURMOUNT-4, is exploring lower 'maintenance doses' that may sustain weight loss with fewer side effects long-term.